Intra-Cellular Therapies Revenue and Competitors

Claim your profile

Location

$674.1M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Intra-Cellular Therapies's estimated annual revenue is currently $70.6M per year.(i)
  • Intra-Cellular Therapies received $150.0M in venture funding in September 2017.
  • Intra-Cellular Therapies's estimated revenue per employee is $145,847
  • Intra-Cellular Therapies's total funding is $674.1M.
  • Intra-Cellular Therapies's current valuation is $3.5B. (January 2022)

Employee Data

  • Intra-Cellular Therapies has 484 Employees.(i)
  • Intra-Cellular Therapies grew their employee count by 24% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M534%N/AN/A
#2
$354.3M533-7%$567.1MN/A
#3
$405.8M2019-1%N/AN/A
#4
$3M3616%N/AN/A
#5
$2.2M278%N/AN/A
#6
$34.4M1711%N/AN/A
#7
$41.2M198-7%N/AN/A
#8
$2.8M3455%N/AN/A
#9
$6.2M7544%N/AN/A
#10
$4.5M5429%N/AN/A

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications. Use link below for a listing of Job Opportunities: https://www.linkedin.com/jobs/search/keywords=intra-cellular%20therapies&location=United%20States&locationId=us%3A0

keywords:Biotechnology,Healthcare,Pharmaceuticals

$674.1M

Total Funding

484

Number of Employees

$70.6M

Revenue (est)

24%

Employee Growth %

$3.5B

Valuation

N/A

Accelerator

Intra-Cellular Therapies News

2022-04-17 - Intra-Cellular Therapies Announces FDA Approval of New ...

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the...

2022-04-17 - Intra-Cellular Therapies initiated at neutral at Piper Sandler on current valuation

Piper Sandler had initiated Intra-Cellular Therapies (NASDAQ:ITCI) with a hold rating saying that the current share price reflects...

2022-04-13 - Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors

NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the...

2021-02-12 - Astel­las, Seagen pave the way for Pad­cev's glob­al roll­out with full con­fir­ma­to­ry da­ta for urothe­lial can­cer in hand

It may be almost the end of the year, but the FDA’s stamina for approvals has persevered. On Monday, Intra-Cellular Therapies secured the regulator’s blessing for its antipsychotic drug, Caplyta, despite two late-stage schizophrenia studies that left much to be desired. But as is custom with mo ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75M4842%N/A
#2
$87.7M484-2%N/A
#3
$75M48422%N/A
#4
$87.9M485N/AN/A
#5
$91.1M486-6%N/A

Intra-Cellular Therapies Funding

DateAmountRoundLead InvestorsReference
2014-02-03$100.2MUndisclosedLeerink Partners LLCArticle
2014-02-06$115.3MUndisclosedLeerink Partners LLCArticle
2015-03-09$106.5MUndisclosedLeerink Partners LLCArticle
2015-03-13$121.4MUndisclosedLeerink Partners LLC,Article
2017-09-29$150.0MUndisclosedJ.P. Morgan Securities LLCArticle